Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/ADAPTIN BIO INC/ EFFECT

Notice of Effectiveness · EFFECT

ADAPTIN BIO INC

APTNOTCEQUITYCurrent

Notice of Effectiveness

Filed Jul 22, 2026Accepted Jul 23, 2026, 12:15 AM EDTCIK 1938571Accession 9999999995-26-002384
View company →Permanent SEC source ↗
Share

Company context

Adaptin Bio, Inc. is a biotechnology company developing novel therapies for oncology and central nervous system disorders. Its mission is to improve patient outcomes in difficult-to-treat cancers by improving and enhancing drug delivery to the brain and other tissues. The Company’s proprietary Brain Bispecific T cell Engager (BRiTE) technology was developed by researchers at the Department of Neurosurgery at Duke University. APTN-101 is FDA-cleared for a Phase 1 clinical trial in glioblastoma (GBM), and other indications are being considered for future studies. For more information, visit www.adaptinbio.com.

Current securities

APTNOTC · EQUITY · Current

Recent company filings

  1. 424B3 filingSep 10, 2026
  2. EFFECT filingSep 9, 2026
  3. S-1 filingAug 28, 2026
  4. 424B3 filingAug 25, 2026
  5. Other EventsAug 25, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.